Daytrana (methylphenidate transdermal system)
Defective Delivery System: Out of specification for mechanical peel and shear.
832 recalls, newest first
Defective Delivery System: Out of specification for mechanical peel and shear.
Defective Delivery System: Out of specification for mechanical peel and shear.
Failed Impurities/Degradation Specification: Presence of unknown impurity observed.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Failed impurities/degradation specification: Out-of-Specification result for total impurity at 4.1% (Limit: NMT 3.0%) during retained sample testing.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs